QuickLinks -- Click here to rapidly navigate through this document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):December 3, 2003
GENZYME CORPORATION
(Exact name of registrant as specified in its charter)
Massachusetts
(State or other jurisdiction
of incorporation or organization) | | 06-1047163
(I.R.S. Employer
Identification No.) |
500 Kendall St., Cambridge, Massachusetts
(Address of principal executive offices) |
|
02142
(zip code) |
(617) 252-7500
(Registrant's telephone number, including area code)
Item 7. Financial Statements, Pro Forma Financial Information And Exhibits.
- (c)
- Exhibits:
| 99 | | Press Release of Genzyme Corporation dated December 3, 2003. |
Item 9. Regulation FD Disclosure
On December 3, 2003, Genzyme Corporation issued a press release announcing its intention to issue convertible notes. A copy of the press release is attached to this Form 8-K as Exhibit 99.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | GENZYME CORPORATION |
|
|
By: |
/s/ MICHAEL S. WYZGA
Michael S. Wyzga
Executive Vice President, Finance,
Chief Financial Officer, and
Chief Accounting Officer |
DATE: December 3, 2003 |
|
|
|
EXHIBIT INDEX
EXHIBIT
NO.
| | DESCRIPTION
|
|---|
| 99 | | Press Release of Genzyme Corporation dated December 3, 2003 |
QuickLinks
SIGNATUREEXHIBIT INDEX
